Tag: post-operative nausea and vomiting market trends

Uncover key drivers, emerging technologies, and competitive movements shaping the post-operative nausea and vomiting market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Post-Operative Nausea And Vomiting Market be in 2030 compared with 2026?

The market for post-operative nausea and vomiting has experienced significant expansion recently. This market is projected to expand from $2.25 billion in 2025 to $2.41 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this growth has been driven by several factors, including a rise in surgical procedure volumes, more extensive application of general anesthesia, the accessibility of serotonin antagonist medications, the development of hospital surgical facilities, and enhanced post-operative care protocols.

The post-operative nausea and vomiting market is projected for substantial expansion over the coming years, reaching $3.13 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.7%. This anticipated growth is linked to factors such as the increasing demand for personalized anesthesia care, greater adoption of preventive antiemetic regimens, the proliferation of ambulatory surgical centers, a heightened focus on patient satisfaction metrics, and increased investments in perioperative care innovation. Key developments expected during this period involve wider implementation of multimodal ponv management strategies, increased application of combination antiemetic therapies, a stronger emphasis on risk-stratified treatment protocols, the expansion of non-pharmacological interventions, and a greater commitment to patient comfort and recovery.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp

What Drivers Are Guiding Growth Patterns In The Post-Operative Nausea And Vomiting Market?

The increasing volume of surgical operations is anticipated to drive the expansion of the Post-Operative Nausea And Vomiting Market in the future. These procedures are medical interventions employing instruments to identify, address, or excise compromised tissues, organs, or irregularities through incision or manipulation. The surge in surgeries can be attributed to innovations in medical technology, making operations safer, more efficient, and less invasive, thereby enhancing patient acceptance and broadening their use. Effective management of post-operative nausea and vomiting improves surgical processes by boosting patient comfort, shortening recovery periods, lowering complication risks, facilitating seamless post-operative care, and ultimately leading to superior surgical results. For example, information from November 2024, provided by the Australian Institute of Health and Welfare, an Australia-based government agency, showed that during the 2023–24 period, 771,600 patients were admitted for surgery from public hospital elective waiting lists, indicating a 4.9% rise compared to 2022–23. Consequently, the escalating number of surgical interventions is propelling the growth of the Post-Operative Nausea And Vomiting Market.

Which Segments Are Driving Activity In The Post-Operative Nausea And Vomiting Market?

The post-operative nausea and vomiting market covered in this report is segmented –

1) By Treatment Type: Serotonin Antagonists, Steroids, Dopamine Antagonists, Neurokinin NK-1 Receptor Antagonists, Non-pharmacological Treatment, Other Treatment Types

2) By Route Of Administration: Oral, Intravenous, Transdermal, Other Route Of Administrations

3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients

4) By Surgical Procedure Type: Orthopedic Surgery, Gynecological Surgery, General Surgery, Cardiac Surgery, Ophthalmic Surgery

5) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegments:

1) By Serotonin Antagonists Type: Ondansetron, Granisetron, Palonosetron, Dolasetron, Tropisetron

2) By Steroids Type: Dexamethasone, Methylprednisolone, Hydrocortisone, Prednisolone, Betamethasone

3) By Dopamine Antagonists Type: Metoclopramide, Droperidol, Prochlorperazine, Domperidone, Chlorpromazine

4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant, Fosaprepitant, Rolapitant, Netupitant, Casopitant

5) By Non-Pharmacological Treatment Type: Acupressure, Aromatherapy, Hypnotherapy, Electroacupuncture, Ginger Supplements

6) By Other Treatment Types: Antihistamines, Anticholinergics, Cannabinoids, Combination Therapy, Herbal & Natural Remedies

What Trends Are Expected To Impact The Competitive Landscape Of The Post-Operative Nausea And Vomiting Market?

Key players in the post-operative nausea and vomiting market are concentrating on developing crucial injectable medications, exemplified by the commercial introduction of regulatory-approved pharmaceutical injectables designed to improve antiemetic therapy in clinical environments. A regulatory-approved commercial launch of such an injectable signifies the market release of an FDA- or authority-approved drug for clinical application, following the completion of all necessary regulatory approvals and compliance protocols. For example, in July 2024, Avenacy, a US-based specialty pharmaceutical company, introduced Palonosetron Hydrochloride Injection in 0.25 mg/5 mL single-dose vials, aiming to assist healthcare providers in reducing dosing errors and enhancing patient safety. This injection is approved for preventing nausea and vomiting induced by chemotherapy and for managing postoperative nausea and vomiting (PONV) for up to 24 hours after surgery, thereby providing a trustworthy treatment solution for patients susceptible to these conditions.

Which Major Industry Participants Are Leading The Post-Operative Nausea And Vomiting Market Growth?

Major companies operating in the post-operative nausea and vomiting market are Pfizer Inc., Merck KGaA, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Baxter Corporation, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Inc., Fresenius Kabi AG, Eisai Co. Ltd., Dr. Reddy’s Laboratories, Cipla Ltd., Alkem Laboratories Ltd., Eagle Pharmaceuticals Inc., Helsinn Healthcare SA, Heron Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Johnson And Johnson, Sanofi, Aurobindo Pharma Ltd., Lupin Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/post-operative-nausea-and-vomiting-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Post-Operative Nausea And Vomiting Market?

North America was the largest region in the post-operative nausea and vomiting market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Post-Operative Nausea And Vomiting Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22109&type=smp

Browse Through More Reports Similar to the Global Post-Operative Nausea And Vomiting Market 2026, By The Business Research Company

Intraoperative Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/intraoperative-imaging-global-market-report

Hospice Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospice-care-global-market-report

Acute Pancreatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the post-operative nausea and vomiting market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Post-Operative Nausea And Vomiting Market be in 2030 compared with 2026?

The market for post-operative nausea and vomiting has experienced significant expansion recently. This market is projected to expand from $2.25 billion in 2025 to $2.41 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this growth has been driven by several factors, including a rise in surgical procedure volumes, more extensive application of general anesthesia, the accessibility of serotonin antagonist medications, the development of hospital surgical facilities, and enhanced post-operative care protocols.

The post-operative nausea and vomiting market is projected for substantial expansion over the coming years, reaching $3.13 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.7%. This anticipated growth is linked to factors such as the increasing demand for personalized anesthesia care, greater adoption of preventive antiemetic regimens, the proliferation of ambulatory surgical centers, a heightened focus on patient satisfaction metrics, and increased investments in perioperative care innovation. Key developments expected during this period involve wider implementation of multimodal ponv management strategies, increased application of combination antiemetic therapies, a stronger emphasis on risk-stratified treatment protocols, the expansion of non-pharmacological interventions, and a greater commitment to patient comfort and recovery.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp

What Drivers Are Guiding Growth Patterns In The Post-Operative Nausea And Vomiting Market?

The increasing volume of surgical operations is anticipated to drive the expansion of the Post-Operative Nausea And Vomiting Market in the future. These procedures are medical interventions employing instruments to identify, address, or excise compromised tissues, organs, or irregularities through incision or manipulation. The surge in surgeries can be attributed to innovations in medical technology, making operations safer, more efficient, and less invasive, thereby enhancing patient acceptance and broadening their use. Effective management of post-operative nausea and vomiting improves surgical processes by boosting patient comfort, shortening recovery periods, lowering complication risks, facilitating seamless post-operative care, and ultimately leading to superior surgical results. For example, information from November 2024, provided by the Australian Institute of Health and Welfare, an Australia-based government agency, showed that during the 2023–24 period, 771,600 patients were admitted for surgery from public hospital elective waiting lists, indicating a 4.9% rise compared to 2022–23. Consequently, the escalating number of surgical interventions is propelling the growth of the Post-Operative Nausea And Vomiting Market.

Which Segments Are Driving Activity In The Post-Operative Nausea And Vomiting Market?

The post-operative nausea and vomiting market covered in this report is segmented –

1) By Treatment Type: Serotonin Antagonists, Steroids, Dopamine Antagonists, Neurokinin NK-1 Receptor Antagonists, Non-pharmacological Treatment, Other Treatment Types

2) By Route Of Administration: Oral, Intravenous, Transdermal, Other Route Of Administrations

3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients

4) By Surgical Procedure Type: Orthopedic Surgery, Gynecological Surgery, General Surgery, Cardiac Surgery, Ophthalmic Surgery

5) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegments:

1) By Serotonin Antagonists Type: Ondansetron, Granisetron, Palonosetron, Dolasetron, Tropisetron

2) By Steroids Type: Dexamethasone, Methylprednisolone, Hydrocortisone, Prednisolone, Betamethasone

3) By Dopamine Antagonists Type: Metoclopramide, Droperidol, Prochlorperazine, Domperidone, Chlorpromazine

4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant, Fosaprepitant, Rolapitant, Netupitant, Casopitant

5) By Non-Pharmacological Treatment Type: Acupressure, Aromatherapy, Hypnotherapy, Electroacupuncture, Ginger Supplements

6) By Other Treatment Types: Antihistamines, Anticholinergics, Cannabinoids, Combination Therapy, Herbal & Natural Remedies

What Trends Are Expected To Impact The Competitive Landscape Of The Post-Operative Nausea And Vomiting Market?

Key players in the post-operative nausea and vomiting market are concentrating on developing crucial injectable medications, exemplified by the commercial introduction of regulatory-approved pharmaceutical injectables designed to improve antiemetic therapy in clinical environments. A regulatory-approved commercial launch of such an injectable signifies the market release of an FDA- or authority-approved drug for clinical application, following the completion of all necessary regulatory approvals and compliance protocols. For example, in July 2024, Avenacy, a US-based specialty pharmaceutical company, introduced Palonosetron Hydrochloride Injection in 0.25 mg/5 mL single-dose vials, aiming to assist healthcare providers in reducing dosing errors and enhancing patient safety. This injection is approved for preventing nausea and vomiting induced by chemotherapy and for managing postoperative nausea and vomiting (PONV) for up to 24 hours after surgery, thereby providing a trustworthy treatment solution for patients susceptible to these conditions.

Which Major Industry Participants Are Leading The Post-Operative Nausea And Vomiting Market Growth?

Major companies operating in the post-operative nausea and vomiting market are Pfizer Inc., Merck KGaA, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Baxter Corporation, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Inc., Fresenius Kabi AG, Eisai Co. Ltd., Dr. Reddy’s Laboratories, Cipla Ltd., Alkem Laboratories Ltd., Eagle Pharmaceuticals Inc., Helsinn Healthcare SA, Heron Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Johnson And Johnson, Sanofi, Aurobindo Pharma Ltd., Lupin Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/post-operative-nausea-and-vomiting-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Post-Operative Nausea And Vomiting Market?

North America was the largest region in the post-operative nausea and vomiting market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Post-Operative Nausea And Vomiting Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22109&type=smp

Browse Through More Reports Similar to the Global Post-Operative Nausea And Vomiting Market 2026, By The Business Research Company

Intraoperative Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/intraoperative-imaging-global-market-report

Hospice Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospice-care-global-market-report

Acute Pancreatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the post-operative nausea and vomiting market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Post-Operative Nausea And Vomiting Market be in 2030 compared with 2026?

The market for post-operative nausea and vomiting has experienced significant expansion recently. This market is projected to expand from $2.25 billion in 2025 to $2.41 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this growth has been driven by several factors, including a rise in surgical procedure volumes, more extensive application of general anesthesia, the accessibility of serotonin antagonist medications, the development of hospital surgical facilities, and enhanced post-operative care protocols.

The post-operative nausea and vomiting market is projected for substantial expansion over the coming years, reaching $3.13 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.7%. This anticipated growth is linked to factors such as the increasing demand for personalized anesthesia care, greater adoption of preventive antiemetic regimens, the proliferation of ambulatory surgical centers, a heightened focus on patient satisfaction metrics, and increased investments in perioperative care innovation. Key developments expected during this period involve wider implementation of multimodal ponv management strategies, increased application of combination antiemetic therapies, a stronger emphasis on risk-stratified treatment protocols, the expansion of non-pharmacological interventions, and a greater commitment to patient comfort and recovery.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp

What Drivers Are Guiding Growth Patterns In The Post-Operative Nausea And Vomiting Market?

The increasing volume of surgical operations is anticipated to drive the expansion of the Post-Operative Nausea And Vomiting Market in the future. These procedures are medical interventions employing instruments to identify, address, or excise compromised tissues, organs, or irregularities through incision or manipulation. The surge in surgeries can be attributed to innovations in medical technology, making operations safer, more efficient, and less invasive, thereby enhancing patient acceptance and broadening their use. Effective management of post-operative nausea and vomiting improves surgical processes by boosting patient comfort, shortening recovery periods, lowering complication risks, facilitating seamless post-operative care, and ultimately leading to superior surgical results. For example, information from November 2024, provided by the Australian Institute of Health and Welfare, an Australia-based government agency, showed that during the 2023–24 period, 771,600 patients were admitted for surgery from public hospital elective waiting lists, indicating a 4.9% rise compared to 2022–23. Consequently, the escalating number of surgical interventions is propelling the growth of the Post-Operative Nausea And Vomiting Market.

Which Segments Are Driving Activity In The Post-Operative Nausea And Vomiting Market?

The post-operative nausea and vomiting market covered in this report is segmented –

1) By Treatment Type: Serotonin Antagonists, Steroids, Dopamine Antagonists, Neurokinin NK-1 Receptor Antagonists, Non-pharmacological Treatment, Other Treatment Types

2) By Route Of Administration: Oral, Intravenous, Transdermal, Other Route Of Administrations

3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients

4) By Surgical Procedure Type: Orthopedic Surgery, Gynecological Surgery, General Surgery, Cardiac Surgery, Ophthalmic Surgery

5) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegments:

1) By Serotonin Antagonists Type: Ondansetron, Granisetron, Palonosetron, Dolasetron, Tropisetron

2) By Steroids Type: Dexamethasone, Methylprednisolone, Hydrocortisone, Prednisolone, Betamethasone

3) By Dopamine Antagonists Type: Metoclopramide, Droperidol, Prochlorperazine, Domperidone, Chlorpromazine

4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant, Fosaprepitant, Rolapitant, Netupitant, Casopitant

5) By Non-Pharmacological Treatment Type: Acupressure, Aromatherapy, Hypnotherapy, Electroacupuncture, Ginger Supplements

6) By Other Treatment Types: Antihistamines, Anticholinergics, Cannabinoids, Combination Therapy, Herbal & Natural Remedies

What Trends Are Expected To Impact The Competitive Landscape Of The Post-Operative Nausea And Vomiting Market?

Key players in the post-operative nausea and vomiting market are concentrating on developing crucial injectable medications, exemplified by the commercial introduction of regulatory-approved pharmaceutical injectables designed to improve antiemetic therapy in clinical environments. A regulatory-approved commercial launch of such an injectable signifies the market release of an FDA- or authority-approved drug for clinical application, following the completion of all necessary regulatory approvals and compliance protocols. For example, in July 2024, Avenacy, a US-based specialty pharmaceutical company, introduced Palonosetron Hydrochloride Injection in 0.25 mg/5 mL single-dose vials, aiming to assist healthcare providers in reducing dosing errors and enhancing patient safety. This injection is approved for preventing nausea and vomiting induced by chemotherapy and for managing postoperative nausea and vomiting (PONV) for up to 24 hours after surgery, thereby providing a trustworthy treatment solution for patients susceptible to these conditions.

Which Major Industry Participants Are Leading The Post-Operative Nausea And Vomiting Market Growth?

Major companies operating in the post-operative nausea and vomiting market are Pfizer Inc., Merck KGaA, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Baxter Corporation, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Inc., Fresenius Kabi AG, Eisai Co. Ltd., Dr. Reddy’s Laboratories, Cipla Ltd., Alkem Laboratories Ltd., Eagle Pharmaceuticals Inc., Helsinn Healthcare SA, Heron Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Johnson And Johnson, Sanofi, Aurobindo Pharma Ltd., Lupin Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/post-operative-nausea-and-vomiting-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Post-Operative Nausea And Vomiting Market?

North America was the largest region in the post-operative nausea and vomiting market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Post-Operative Nausea And Vomiting Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22109&type=smp

Browse Through More Reports Similar to the Global Post-Operative Nausea And Vomiting Market 2026, By The Business Research Company

Intraoperative Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/intraoperative-imaging-global-market-report

Hospice Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospice-care-global-market-report

Acute Pancreatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Projected Valuation Of The Post-Operative Nausea And Vomiting Market In The Coming Years?

The market for post-operative nausea and vomiting has experienced significant expansion in past years. It is projected to rise from a value of $2.11 billion in 2024 to $2.25 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. Factors contributing to the growth recorded in the historical period include increased research and development initiatives, a growing need for innovative therapies, a surge in healthcare spending, a heightened emphasis on personalized medicine, and a rising uptake of digital health technologies.

It is anticipated that the market size for post-operative nausea and vomiting will experience substantial growth in the coming years, reaching a value of $2.94 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 6.9%. This upward projection during the forecast period is linked to the increasing demand for pharmaceuticals, growth in combination therapy, heightened consciousness and investment in healthcare, expansion of the elderly population, and a surge in cancer cases. Prominent trends projected for the forecast period include enhanced antiemetic therapies, strategic partnerships, innovative drug development, the incorporation of sophisticated diagnostic tools, and the use of electronic simulation devices.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Post-Operative Nausea And Vomiting Market?

The surge in the number of surgical procedures is anticipated to accelerate the expansion of the post-operative nausea and vomiting market in the future. These procedures, which involve employing medical instruments to diagnose, treat, or extract damaged tissues, organs, or anomalies through surgical manipulation or incision, are seeing an upward trend. This rise is attributable to medical technology advancements, making surgeries safer, more efficient, and minimally invasive, leading to patient acceptance and broader usage. The management of post-operative nausea and vomiting enhances surgical procedures by improving patient comfort, shortening recovery time, minimizing complication risks, facilitating better post-operative care, and ultimately boosting overall surgical results. For example, data from the Australian Institute of Health and Welfare, a government agency based in Australia, in November 2024 revealed that during the 2023-24 period, the number of patients admitted for surgery from public hospital elective surgery waiting lists stood at 771,600, marking a 4.9% increase in comparison to the 2022–23 period. Consequently, the increasing number of surgical procedures is stimulating the development of the post-operative nausea and vomiting market.

Which Sub-Segments Are Driving Growth Within The Post-Operative Nausea And Vomiting Market?

The post-operative nausea and vomitingmarket covered in this report is segmented –

1) By Treatment Type: Serotonin Antagonists; Steroids; Dopamine Antagonists; Neurokinin NK-1 Receptor Antagonists; Non-pharmacological Treatment; Other Treatment Types

2) By Route Of Administration: Oral; Intravenous; Transdermal; Other Route Of Administrations

3) By Patient Demographics: Pediatric Patients; Adult Patients; Geriatric Patients

4) By Surgical Procedure Type: Orthopedic Surgery; Gynecological Surgery; General Surgery; Cardiac Surgery; Ophthalmic Surgery

5) By End-User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics; Other End-Users

Subsegments:

1) By Serotonin Antagonists Type: Ondansetron; Granisetron; Palonosetron; Dolasetron; Tropisetron

2) By Steroids Type: Dexamethasone; Methylprednisolone; Hydrocortisone; Prednisolone; Betamethasone

3) By Dopamine Antagonists Type: Metoclopramide; Droperidol; Prochlorperazine; Domperidone; Chlorpromazine

4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant; Fosaprepitant; Rolapitant; Netupitant; Casopitant

5) By Non-Pharmacological Treatment Type: Acupressure; Aromatherapy; Hypnotherapy; Electroacupuncture; Ginger Supplements

6) By Other Treatment Types: Antihistamines; Anticholinergics; Cannabinoids; Combination Therapy; Herbal & Natural Remedies

What Key Trends Are Driving Growth In The Post-Operative Nausea And Vomiting Market?

Key players in the post-operative nausea and vomiting market are developing injectable medications with advanced emulsions and sustained-release technologies to enhance effectiveness and provide longer symptom relief for surgical patients. For instance, in July 2024, Avenacy, a US specialty pharma company, launched Palonosetron Hydrochloride Injection in single-dose vials to reduce dosing errors and enhance patient safety. This injection is used to prevent chemotherapy-induced nausea and vomiting as well as post-operative nausea and vomiting, providing up to 24 hours of symptom control.

Which Players Are Shaping The Competitive Landscape Of The Post-Operative Nausea And Vomiting Market?

Major companies operating in the post-operative nausea and vomiting market are Pfizer Inc., Merck KGaA, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited. , Baxter Corporation, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Inc., Fresenius Kabi AG, Eisai Co. Ltd., Dr. Reddy’s Laboratories, Kyowa Hakko Kirin Taiwan Co. Ltd., Cipla Ltd., Alkem Laboratories Ltd., Eagle Pharmaceuticals Inc. , Camurus AB, Helsinn Healthcare SA, Heron Therapeutics Inc., Advacare Pharma

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/post-operative-nausea-and-vomiting-global-market-report

How Do Regional Dynamics Influence The Post-Operative Nausea And Vomiting Market Performance?

North America was the largest region in the post-operative nausea and vomiting market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=22109&type=smp

Browse Through More Reports Similar to the Global Post-Operative Nausea And Vomiting Market 2025, By The Business Research Company

Antiemetics And Antinauseants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiemetics-and-antinauseants-global-market-report

Chemotherapy Induced Nausea And Vomiting Cinv Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

Chemotherapy Induced Nausea And Vomiting Cinv Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Post-Operative Nausea And Vomiting Market Expected To Become By 2029 Compared With Its 2025 Level?

Recent years have witnessed robust expansion in the post-operative nausea and vomiting market size. This market is anticipated to expand from $2.11 billion in 2024 to $2.25 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.8%. The historical growth experienced by the market can be ascribed to several factors, including heightened research and development activities, an escalating demand for sophisticated therapies, an increase in healthcare expenditure, a stronger emphasis on personalized medicine, and the expanding integration of digital health technologies.

The post-operative nausea and vomiting market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $2.94 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.9%. Several factors contribute to this growth during the projection period, including an increasing need for pharmaceuticals, the proliferation of combination therapy, heightened awareness coupled with greater healthcare investments, an expanding elderly demographic, and a growing incidence of cancer. Key developments expected within the forecast timeframe encompass advanced antiemetic treatments, collaborative strategies, novel drug formulations, the incorporation of sophisticated diagnostic instruments, and electronic simulation technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp

Which Factors And Drivers Are Influencing The Post-Operative Nausea And Vomiting Market In 2025?

The increasing volume of surgical operations is anticipated to drive expansion in the post-operative nausea and vomiting market in the future. These procedures involve medical interventions employing instruments to identify, address, or extract compromised tissues, organs, or anomalies through incision or manipulation. The escalation in surgical volumes stems from progress in medical technology, making operations safer, more efficacious, and less invasive, thus boosting patient willingness and broader utilization. Effective management of post-operative nausea and vomiting improves surgical processes by elevating patient comfort, shortening recovery periods, lowering complication risks, facilitating seamless post-operative care, and ultimately bettering overall surgical results. For example, data from November 2024, released by the Australian Institute of Health and Welfare, an Australian government body, indicated that during the 2023–24 timeframe, 771,600 patients underwent surgery from public hospital elective waiting lists. This figure represents a 4.9% rise when contrasted with 2022–23. Consequently, the growing frequency of surgical interventions is a key factor propelling the expansion of the post-operative nausea and vomiting market.

How Is The Post-Operative Nausea And Vomiting Market Segmented?

The post-operative nausea and vomitingmarket covered in this report is segmented –

1) By Treatment Type: Serotonin Antagonists; Steroids; Dopamine Antagonists; Neurokinin NK-1 Receptor Antagonists; Non-pharmacological Treatment; Other Treatment Types

2) By Route Of Administration: Oral; Intravenous; Transdermal; Other Route Of Administrations

3) By Patient Demographics: Pediatric Patients; Adult Patients; Geriatric Patients

4) By Surgical Procedure Type: Orthopedic Surgery; Gynecological Surgery; General Surgery; Cardiac Surgery; Ophthalmic Surgery

5) By End-User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics; Other End-Users

Subsegments:

1) By Serotonin Antagonists Type: Ondansetron; Granisetron; Palonosetron; Dolasetron; Tropisetron

2) By Steroids Type: Dexamethasone; Methylprednisolone; Hydrocortisone; Prednisolone; Betamethasone

3) By Dopamine Antagonists Type: Metoclopramide; Droperidol; Prochlorperazine; Domperidone; Chlorpromazine

4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant; Fosaprepitant; Rolapitant; Netupitant; Casopitant

5) By Non-Pharmacological Treatment Type: Acupressure; Aromatherapy; Hypnotherapy; Electroacupuncture; Ginger Supplements

6) By Other Treatment Types: Antihistamines; Anticholinergics; Cannabinoids; Combination Therapy; Herbal & Natural Remedies

What Trends Are Expected To Drive The Post-Operative Nausea And Vomiting Market?

Leading companies in the post-operative nausea and vomiting market are concentrating on developing crucial injectable medications that use advanced emulsion formulations and sustained-release technology. This effort aims to improve efficacy and deliver extended symptom relief for surgical patients. Critical injectable medications are defined as essential drugs administered via injection, designed to offer immediate and effective treatment for serious or urgent medical conditions. For instance, in July 2024, Avenacy, a US-based specialty pharmaceutical company, launched Palonosetron Hydrochloride Injection in 0.25 mg/5 mL single-dose vials, intended to help healthcare providers reduce dosing errors and enhance patient safety. This injection is indicated for preventing nausea and vomiting caused by chemotherapy and for managing postoperative nausea and vomiting (PONV) for up to 24 hours following surgery, providing a reliable treatment option for patients at risk of these conditions.

Which Key Players Are Driving Competition In The Post-Operative Nausea And Vomiting Market?

Major companies operating in the post-operative nausea and vomiting market are Pfizer Inc., Merck KGaA, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited. , Baxter Corporation, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Inc., Fresenius Kabi AG, Eisai Co. Ltd., Dr. Reddy’s Laboratories, Kyowa Hakko Kirin Taiwan Co. Ltd., Cipla Ltd., Alkem Laboratories Ltd., Eagle Pharmaceuticals Inc. , Camurus AB, Helsinn Healthcare SA, Heron Therapeutics Inc., Advacare Pharma

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/post-operative-nausea-and-vomiting-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Post-Operative Nausea And Vomiting Market?

North America was the largest region in the post-operative nausea and vomiting market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Post-Operative Nausea And Vomiting Market Report:

https://www.thebusinessresearchcompany.com/customise?id=22109&type=smp

Browse Through More Reports Similar to the Global Post-Operative Nausea And Vomiting Market 2025, By The Business Research Company

Antiemetics And Antinauseants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiemetics-and-antinauseants-global-market-report

Chemotherapy Induced Nausea And Vomiting Cinv Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

Chemotherapy Induced Nausea And Vomiting Cinv Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Projected CAGR for the Post-Operative Nausea And Vomiting Market Size from 2025 to 2034?

In recent years, the market for post-operative nausea and vomiting has witnessed significant growth. The market is projected to expand from $2.11 billion in 2024 to $2.25 billion in 2025, recording a compound annual growth rate (CAGR) of 6.8%. The growth in the previous period is credited to increased research and development activities, rising demand for innovative therapies, a surge in healthcare spending, a heightened emphasis on personalized medicine, and wider adoption of digital health technologies.

Over the coming years, the market size of post-operative nausea and vomiting is projected to experience robust growth, reaching$2.94 billion by 2029, escalating at a compound annual growth rate (CAGR) of 6.9%. This growth in the forecast period is due to a number of factors including an increasing demand for pharmaceuticals, the rise of combination therapy, elevated healthcare investments, growing awareness, an aging population, and an increase in cancer cases. Trends in this forecast period encompass advanced antiemetic therapies, strategic partnerships, novel drug formulations, the incorporation of high-tech diagnostic tools and electronic simulation devices.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp

What Are the Core Market Drivers Propelling Growth in the Post-Operative Nausea And Vomiting Industry?

The increase in surgical procedures is anticipated to boost the expansion of the market for post-operative nausea and vomiting. Surgical procedures in medicine are defined as operations using tools to identify, cure, or eradicate unhealthy tissue, organs, or irregularities by cutting or manipulation. Today, the rate of surgeries is accelerating due to the breakthroughs in medical innovation, making surgical procedures more patient-friendly, efficient, and less intrusive, thus increasing wider adoption and patient trust. Post-operative nausea and vomiting control heighten the effectiveness of surgical procedures by enhancing patient comfort, shortening recovery span, lessening the chance of complications, ensuring better post-operative supervision, and eventually, improving the overall results of the surgery. For example, as reported by the Australian Institute of Health and Welfare, a government agency based in Australia, in the period of 2023-24, there was a 4.9% increase in patients admitted for surgery from public hospital elective surgery waiting lists. This was as many as 771,600 patients comparing to the figures of 2022–23. Conclusively, the surge in surgical procedures is fostering the expansion of the market for post-operative nausea and vomiting.

How Is the Post-Operative Nausea And Vomiting Market Segmented?

The post-operative nausea and vomitingmarket covered in this report is segmented –

1) By Treatment Type: Serotonin Antagonists; Steroids; Dopamine Antagonists; Neurokinin NK-1 Receptor Antagonists; Non-pharmacological Treatment; Other Treatment Types

2) By Route Of Administration: Oral; Intravenous; Transdermal; Other Route Of Administrations

3) By Patient Demographics: Pediatric Patients; Adult Patients; Geriatric Patients

4) By Surgical Procedure Type: Orthopedic Surgery; Gynecological Surgery; General Surgery; Cardiac Surgery; Ophthalmic Surgery

5) By End-User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics; Other End-Users

Subsegments:

1) By Serotonin Antagonists Type: Ondansetron; Granisetron; Palonosetron; Dolasetron; Tropisetron

2) By Steroids Type: Dexamethasone; Methylprednisolone; Hydrocortisone; Prednisolone; Betamethasone

3) By Dopamine Antagonists Type: Metoclopramide; Droperidol; Prochlorperazine; Domperidone; Chlorpromazine

4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant; Fosaprepitant; Rolapitant; Netupitant; Casopitant

5) By Non-Pharmacological Treatment Type: Acupressure; Aromatherapy; Hypnotherapy; Electroacupuncture; Ginger Supplements

6) By Other Treatment Types: Antihistamines; Anticholinergics; Cannabinoids; Combination Therapy; Herbal & Natural Remedies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22109&type=smp

Which Regions Are Driving the Next Phase of the Post-Operative Nausea And Vomiting Market Growth?

North America was the largest region in the post-operative nausea and vomiting market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Post-Operative Nausea And Vomiting Industry?

Key players in the post-operative nausea and vomiting market are concentrating on the creation of crucial injectable medications via the utilization of advanced emulsion formulations and sustained-release technology. The aim is to enhance effectiveness and provide extended relief from symptoms for patients after surgery. These crucial injectable medications are essentially drugs administered through injection, intended to offer immediate and potent treatment for severe or emergency health conditions. For example, Avenacy, a specialty pharmaceutical company situated in the US, introduced Palonosetron Hydrochloride Injection in 0.25 mg/5 mL single-dose vials in July 2024. The aim was to assist healthcare professionals in minimising dosing errors and promoting patient safety. This injection is recommended for preventing nausea and vomiting induced by chemotherapy and for managing post-operative nausea and vomiting for up to 24 hours post surgery. This provides a trustworthy treatment alternative for patients susceptible to these conditions.

View the full report here:

https://www.thebusinessresearchcompany.com/report/post-operative-nausea-and-vomiting-global-market-report

How Is the Post-Operative Nausea And Vomiting Market Defined and What Are Its Core Parameters?

Post-operative nausea and vomiting (PONV) is a common complication that occurs within 24 to 48 hours after surgery, often resulting from anesthesia, pain medications, or the body’s response to surgical stress. It can significantly affect a patient’s recovery, causing discomfort, delayed healing, and an increased risk of complications like dehydration or electrolyte imbalance.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22109

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Post-Operative Nausea And Vomiting Market?

There has been substantial expansion in the market size of post-operative nausea and vomiting in the past few years. The market, valued at $2.11 billion in 2024, is projected to escalate to $2.26 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.4%. This remarkable increase during the historic period can be credited to the escalation in research and development activities, growing inclination for progressive therapies, an uptrend in the expenditure on healthcare, augmented emphasis on personalized medicine, as well as the increasing embrace of digital health technologies.

What Growth Rate Is Forecasted for the Post-Operative Nausea And Vomiting Market by 2029?

In the coming years, the market size for post-operative nausea and vomiting is projected to witness a robust expansion. The market is forecasted to reach $2.97 billion in 2029, with a compound annual growth rate (CAGR) of 7.0%. Several factors contribute to this predicted growth, including an increased demand for pharmaceuticals, the rise of combination therapy, enhanced awareness and investment in healthcare, a surge in the elderly population, and an increase in cancer cases. Key trends anticipated during the forecast period consist of the development of superior antiemetic therapies, strategic affiliations, the introduction of novel drug compositions, the incorporation of cutting-edge diagnostic tools, and the use of electronic simulation devices.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp

Which Key Companies Are Shaping the Future of the Post-Operative Nausea And Vomiting Market?

Major companies operating in the post-operative nausea and vomiting market are Pfizer Inc., Merck KGaA, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited. , Baxter Corporation, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Inc., Fresenius Kabi AG, Eisai Co. Ltd., Dr. Reddy’s Laboratories, Kyowa Hakko Kirin Taiwan Co. Ltd., Cipla Ltd., Alkem Laboratories Ltd., Eagle Pharmaceuticals Inc. , Camurus AB, Helsinn Healthcare SA, Heron Therapeutics Inc., Advacare Pharma

Which Factors Are Driving Demand in the Post-Operative Nausea And Vomiting Industry?

The post-operative nausea and vomiting market is anticipated to expand due to an increase in the number of surgical procedures. Surgical procedures encompass medical interventions that employ instruments to diagnose, treat, or dissect damaged tissues, organs, or anomalies through cutting or manipulation. Owing to advancements in medical technology, surgical processes have become safer, more effective, and less invasive, thereby gaining acceptance from patients and wider applicability. The management of post-operative nausea and vomiting optimises surgical procedures by improving patient comfort, decreasing recovery duration, lessening the risk of complications, facilitating improved post-operative care, and enhancing the overall outcomes of the surgery. For instance, records from the Australian Institute of Health and Welfare, a government agency based in Australia, indicated that 771,600 patients were admitted for surgical procedures from public hospital elective surgery waiting lists in November 2024, marking a 4.9% surge compared to 2022-23. Consequently, the increasing surgical procedures are fuelling the growth of the post-operative nausea and vomiting market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=22109&type=smp

How Is the Post-Operative Nausea And Vomiting Market Segmented by Several Divisions?

The post-operative nausea and vomiting market covered in this report is segmented –

1) By Treatment Type: Serotonin Antagonists, Steroids, Dopamine Antagonists, Neurokinin NK-1 Receptor Antagonists, Non-pharmacological Treatment, Other Treatment Types

2) By Route Of Administration: Oral, Intravenous, Transdermal, Other Route Of Administrations

3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients

4) By Surgical Procedure Type: Orthopedic Surgery, Gynecological Surgery, General Surgery, Cardiac Surgery, Ophthalmic Surgery

5) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegmentss:

1) By Serotonin Antagonists Type: Ondansetron, Granisetron, Palonosetron, Dolasetron, Tropisetron

2) By Steroids Type: Dexamethasone, Methylprednisolone, Hydrocortisone, Prednisolone, Betamethasone

3) By Dopamine Antagonists Type: Metoclopramide, Droperidol, Prochlorperazine, Domperidone, Chlorpromazine

4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant, Fosaprepitant, Rolapitant, Netupitant, Casopitant

5) By Non-Pharmacological Treatment Type: Acupressure, Aromatherapy, Hypnotherapy, Electroacupuncture, Ginger Supplements

6) By Other Treatment Types: Antihistamines, Anticholinergics, Cannabinoids, Combination Therapy, Herbal & Natural Remedies

What are the Emerging Market Trends Driving the Growth of the Post-Operative Nausea And Vomiting Industry?

Major businesses in the post-operative nausea and vomiting market are prioritizing the creation of vital injectable drugs. They are using advanced emulsion formulations and prolonged-release technology to enhance efficiency and provide long-term relief for patients after surgery. These critical injectable medications refer to vital drugs given through injections, formulated to offer quick and effective treatment for severe or pressing health issues. For example, Avenacy, a specialty pharmaceutical company based in the US, launched Palonosetron Hydrochloride Injection in 0.25 mg/5 mL single-dose vials in July 2024. This initiative was to help healthcare professionals minimize dosing mistakes and increase patient safety. The injection is used to prevent nausea and vomiting resulting from chemotherapy and to control postoperative nausea and vomiting (PONV) for up to 24 hours after a surgical procedure. It provides a dependable treatment alternative for patients who are susceptible to these conditions.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/post-operative-nausea-and-vomiting-global-market-report

Which Regions Are Driving Growth in the Post-Operative Nausea And Vomiting Market?

North America was the largest region in the post-operative nausea and vomiting market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22109

This Report Delivers Insight On:

1. How big is the post-operative nausea and vomiting market, and how is it changing globally?

2. Who are the major companies in the post-operative nausea and vomiting market, and how are they performing?

3. What are the key opportunities and risks in the post-operative nausea and vomiting market right now?

4. Which products or customer segments are growing the most in the post-operative nausea and vomiting market?

5. What factors are helping or slowing down the growth of the post-operative nausea and vomiting market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the post-operative nausea and vomiting industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Post-Operative Nausea And Vomiting Market In 2029?

The market size for post-operative nausea and vomiting has experienced considerable growth in the recent past. Predictions indicate an increase from $2.11 billion in 2024 to $2.26 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.4%. The historic growth period was influenced by factors such as increased research and development activities, a higher demand for advanced therapeutic methods, an uptick in healthcare spending, a greater emphasis on personalized medicine, and the increased uptake of digital health technologies.

Predictions point towards a steady expansion of the post-operative nausea and vomiting market over the upcoming years. The market is forecasted to reach $2.97 billion by 2029, maintaining a compound annual growth rate (CAGR) of 7.0%. Factors contributing to this projected growth include the escalating demand for pharmaceuticals, the uptake in combination therapy, heightened awareness, investments in healthcare, an expanding geriatric population, and an increasing incidence of cancer cases. The period under forecast can expect to see trends such as progressive antiemetic therapies, strategic alliances, inventive pharmaceutical formulations, the deployment of cutting-edge diagnostic tools, and the incorporation of electronic simulation devices.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Post-Operative Nausea And Vomiting Market?

The growth of the post-operative nausea and vomiting market is expected to be driven by the increasing number of surgical procedures. Surgical operations, which involve the use of tools to identify, cure, or eliminate malfunctioning tissues or organs through cutting or manipulation, are on the rise. This surge is a result of advancements in medical technology that have made procedures safer, more effective, and less invasive, thereby increasing patient approval and broader usage. Post-operative nausea and vomiting management enhances surgical procedures by enhancing patient comfort, reducing recovery periods, lessening the likelihood of complications, ensuring more effective post-operative care, and ultimately improving overall surgical results. For example, the Australian Institute of Health and Welfare reported in November 2024 that in 2023-24, admissions for surgery from public hospital elective surgery waiting lists increased by 4.9% compared to 2022-23, with a total of 771,600 patients. Consequently, the growing number of surgical procedures is fuelling the expansion of the post-operative nausea and vomiting market.

Which Key Market Segments Comprise the Post-Operative Nausea And Vomiting Market and Drive Its Revenue Growth?

The post-operative nausea and vomiting market covered in this report is segmented –

1) By Treatment Type: Serotonin Antagonists, Steroids, Dopamine Antagonists, Neurokinin NK-1 Receptor Antagonists, Non-pharmacological Treatment, Other Treatment Types

2) By Route Of Administration: Oral, Intravenous, Transdermal, Other Route Of Administrations

3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients

4) By Surgical Procedure Type: Orthopedic Surgery, Gynecological Surgery, General Surgery, Cardiac Surgery, Ophthalmic Surgery

5) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegmentss:

1) By Serotonin Antagonists Type: Ondansetron, Granisetron, Palonosetron, Dolasetron, Tropisetron

2) By Steroids Type: Dexamethasone, Methylprednisolone, Hydrocortisone, Prednisolone, Betamethasone

3) By Dopamine Antagonists Type: Metoclopramide, Droperidol, Prochlorperazine, Domperidone, Chlorpromazine

4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant, Fosaprepitant, Rolapitant, Netupitant, Casopitant

5) By Non-Pharmacological Treatment Type: Acupressure, Aromatherapy, Hypnotherapy, Electroacupuncture, Ginger Supplements

6) By Other Treatment Types: Antihistamines, Anticholinergics, Cannabinoids, Combination Therapy, Herbal & Natural Remedies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22109&type=smp

Which Areas Are Leading Regions in the Post-Operative Nausea And Vomiting Market Expansion Across the Globe?

North America was the largest region in the post-operative nausea and vomiting market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in thePost-Operative Nausea And Vomiting Market Over the Coming Years?

Leading corporations operating within the post-operative nausea and vomiting Market are concentrating on creating crucial injectable drugs with the use of advanced emulsion formulations and extended-release technology to enhance the effectiveness and extend symptom aid for patients after surgery. The term ‘critical injectable medications’ refers to vital drugs administered through injection intended to offer immediate and potent treatment for severe or critical medical situations. For instance, in July 2024, Avenacy, an American speciality pharmaceutical company, introduced Palonosetron Hydrochloride Injection in 0.25 mg/5 ml single-dose vials, aimed at assisting healthcare professionals to minimize dosage mistakes and upgrade patient safety. This injection is used for the prevention of nausea and vomiting resulting from chemotherapy and to control postoperative nausea and vomiting (PONV) for approximately 24 hours following surgery, making it a trustworthy treatment choice for patients vulnerable to these conditions.

View the full report here:

https://www.thebusinessresearchcompany.com/report/post-operative-nausea-and-vomiting-global-market-report

How Is the Post-Operative Nausea And Vomiting Market Conceptually Defined?

Post-operative nausea and vomiting (PONV) is a common complication that occurs within 24 to 48 hours after surgery, often resulting from anesthesia, pain medications, or the body’s response to surgical stress. It can significantly affect a patient’s recovery, causing discomfort, delayed healing, and an increased risk of complications like dehydration or electrolyte imbalance.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22109

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model